LONG-TERM REAL-WORLD COMPARISON OF IL-17A AND TNF-Α INHIBITION IN ANKYLOSING SPONDYLITIS: SECUKINUMAB VS INFLIXIMAB

Authors

  • Sardorbek Rakhimov MD Tashkent State Medical University Author
  • Javohir Mullokulov MD Tashkent State Medical University Author

Keywords:

To compare the long-term efficacy and safety of intravenous Secukinumab (150 mg) versus Infliximab in patients with AS over a 24-month follow-up period.

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton that leads to pain, stiffness, and progressive structural damage. Biologics targeting TNF-α and IL-17A have revolutionized treatment. While Infliximab remains a widely used TNF inhibitor, Secukinumab, an IL-17A inhibitor, is increasingly considered an alternative. Real-world head-to-head data remain limited.

References

1.2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. https://doi.org/10.1136/annrheumdis-2016-210770

2.Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. https://doi.org/10.1056/nejmoa1505066

Downloads

Published

2026-10-17